ABSTRACT
No disponible
Subject(s)
Humans , Coronavirus Infections/diagnosis , Serologic Tests/standards , Enzyme-Linked Immunosorbent Assay/standards , Serologic Tests/methods , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity , Reference Standards , Severe acute respiratory syndrome-related coronavirus/isolation & purificationABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Meningitis, Listeria/drug therapy , Listeriosis/drug therapy , Listeria monocytogenes/isolation & purification , Meningitis, Listeria/microbiology , Leukocytosis/microbiology , Cerebrospinal Fluid/microbiology , Listeriosis/diagnosis , Pharyngitis/diagnosis , Pharyngitis/drug therapy , Ceftriaxone/therapeutic use , Vancomycin/therapeutic use , Cerebrospinal Fluid , Risk FactorsSubject(s)
Meningitis, Listeria/diagnosis , Aged , Humans , Male , Multiplex Polymerase Chain ReactionABSTRACT
No disponible
Subject(s)
Female , Middle Aged , Humans , Lymphoma, Non-Hodgkin/complications , Aspergillosis/complications , Dermatomycoses/diagnosis , Aspergillus fumigatus/pathogenicitySubject(s)
Bacteriological Techniques , Endocarditis, Bacterial/microbiology , Gram-Negative Bacterial Infections/microbiology , Microbial Sensitivity Tests , Ochrobactrum anthropi/isolation & purification , Postoperative Complications/microbiology , Prosthesis-Related Infections/microbiology , Heart Valve Prosthesis/adverse effects , Heart Valve Prosthesis Implantation , Humans , Immunocompetence , Mitral Valve/microbiology , Ochrobactrum anthropi/drug effects , Ochrobactrum anthropi/growth & developmentABSTRACT
INTRODUCTION: Antifungal therapy for mucosal candidiasis caused by fluconazole-resistant Candida species is problematic. The aim of this study was to investigate the in vitro activity of caspofungin against Candida strains with reduced susceptibility to fluconazole isolated from HIV-infected patients. METHODS: The in vitro activity of caspofungin was assessed in 28 fluconazole-resistant Candida isolates obtained from the oral cavity of a cohort of 174 consecutive HIV-infected patients. Minimum inhibitory concentrations (MICs) were determined by a standardized broth microdilution method, as recommended by the NCCLS. RESULTS: Overall, caspofungin MICs ranged from < or = 0.06 microg/ml to 1 microg/ml. MICs at which 50% (MIC50) and 90% (MIC90) of isolates were inhibited were 0.25 microg/ml and 0.5 microg/ml, respectively. MICs ranged from < or = 0.06 microg/ml to 0.5 microg/ml for Candida albicans (n = 11), and < 0.06 microg/ml to 1 microg/ml or Candida glabrata (n = 11). MICs for the two strains of Candida krusei were 0.125 microg/ml and 1 microg/ml. The range of MICs for Candida tropicalis and Candida inconspicua strains was 0.25 microg/ml to 0.5 microg/ml. CONCLUSION: Caspofungin was very active in vitro against a variety of fluconazole-resistant Candida strains recovered from a clinical cohort of HIV-infected patients. The MIC50 values and MIC ranges were slightly higher for Candida glabrata than for Candida albicans.
